Adverse events in HIV-infected persons receiving antiretroviral drug regimens in a large urban slum in Nairobi, Kenya, 2003-2005

Journal of the International Association of Physicians in AIDS Care

Volumn 6, Issue 3, 2007, Pages 206-209

  Kim, Andrea A ^a   Wanjiku, Lucy ^b   MacHaria, Doris K ^b   Wangai, Mary ^c   Isavwa, Anthony ^b   Abdi, Hussein ^b   Marston, Barbara J ^b   Ilako, Festus ^d   Kjaer, Mette ^d   Chebet, Kenneth ^c   De Cock, Kevin M ^b   Weidle, Paul J ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Centers for Disease Control and Prevention Kenya   (Kenya)

^c MINISTRY OF HEALTH   (Kenya)

^d AMREF HEALTH AFRICA   (Kenya)

Author keywords

Africa; antiretroviral therapy; HIV; nonnucleoside reverse transcriptase inhibitor; toxicity

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

HIV INFECTIONS; HUMAN; KENYA; POVERTY;

ANTI-HIV AGENTS; HIV INFECTIONS; HUMANS; KENYA; POVERTY AREAS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 53849133546     PISSN: 15451097     EISSN: 15570886     Source Type: Journal    
DOI: 10.1177/1545109707304494     Document Type: Article

References (24)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). 2006 Report on the Global AIDS Epidemic: A UNAIDS 10th Anniversary Special Edition. Geneva, Switzerland: UNAIDS ; 2006.
2. Office of the Global AIDS Coordinator (OGAC). The President's Emergency Plan for AIDS Relief: A U.S. Five-Year HIV/AIDS Global Strategy. Washington, DC: OGAC ; 2004.
3. The Global Fund to Fight AIDS, Tuberculosis, and Malaria. The framework document to the Global Fund to Fight AIDS, Tuberculosis, and Malaria. http://www.theglobalfund.org/en/files/publicdoc/Framework-uk.pdf. Published October 2003. Accessed June 13, 2006.
4. World Health Organization. Treating 3 million people by 2005: making it happen: the WHO strategy. http://www.who.int/hiv/pub/guidelines/adult/en/index. html. Published 2003. Accessed August 23, 2006.
5. Department of Health and Human Services (DHHS). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents: October 6, 2005. Washington, DC: DHHS ; 2005.
6. Macharia D., Ngan'ga LW, Wangai M., Isavwa A., Ilako F., Marston B., De Cock KM, Weidle PJ Implementing an antiretroviral treatment program in a Nairobi slum, Kenya. IAS Conf HIV Pathog Treat. July 2005.
7. Central Bureau of Statistics, Republic of Kenya Ministry of Planning and National Development. Kenya 1999 population census. Nairobi, Kenya; 1999.
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Recommendations for a public health approach, 2006 revision. Geneva, Switzerland: WHO ; 2006.
9. National AIDS and STD Control Programme. Guidelines to Antiretroviral Drug Therapy in Kenya. 3 rd ed. Nairobi, Kenya: Republic of Kenya, Ministry of Health ; July 2003.
10. van Leth F., Phanuphak P., Ruxrungtham K., et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet. 2004 ; 363: 1253-1263. (Pubitemid 38496486)
11. Laurent C., Kouanfack C., Koulla-Shiro S., et al. Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial. Lancet. 2004 ; 364 (9428). 29-34. (Pubitemid 38968622)
12. Idigbe E., Adewole T., Eisen G., et al. Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program. J Acquir Immune Defic Syndr. 2005 ; 40 (1). 65-69. (Pubitemid 41233207)
13. Spacek L., Shihab H., Kamya R., et al. Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis. 2006 ; 42 (2). 252-259. (Pubitemid 43054199)
14. Kebba A., Twine D., Mwebaze R., et al. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral nave HIV type 1-infected Ugandan patients. AIDS Res Hum Retroviruses. 2002 ; 18 (16). 1181-1187. (Pubitemid 35370606)
15. Wester C., Kim S., Bussmann H., et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005 ; 40 (3). 336-343. (Pubitemid 41533075)
16. van Oosterhout J., Bodasing N., Kumwenda J., et al. Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi. Trop Med Int Health. 2005 ; 10 (5). 464-470. (Pubitemid 40712431)
17. Coetzee D., Hildebrand K., Boulle A., et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004 ; 18 (6). 887-895. (Pubitemid 38553709)
18. Jack C., Lalloo U., Karim Q., et al. A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004 ; 36 (4). 929-934. (Pubitemid 38944088)
19. Hudspeth J., Venter W., Van Rie A., et al. Access to and early outcomes of a public South African adult antiretroviral clinic. Southern African J Epidemiol Infect. 2004 ; 19 (2). 48-51.
20. Sanne I., Mommeja-Marin H., Hinkle J., et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005 ; 191: 825-829. (Pubitemid 40349795)
21. Calmy A., Pinoges L., Szumilin E., et al. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort. AIDS. 2006 ; 20: 1164-1169.
22. Food and Drug Administration (FDA). FDA public health advisory for nevirapine (viramune). http://www.fda.gov/oashi/aids/listserve/archive.html. Accessed June 13, 2006.
23. Severe P., Leger P., Charles M., et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005 ; 353 (22). 2325-2334. (Pubitemid 41713744)
24. Tassie J., Szumilin E., Calmy A., et al. Highly active antiretroviral therapy in resource-poor settings: the experience of Medecins Sans Frontieres. AIDS. 2003 ; 17 (13). 1995-1997. (Pubitemid 37074829)